#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1.
1-1	0-2	1.	_	_	_	_

#Text=Introduction
2-1	3-15	Introduction	abstract	new	_	_

#Text=Rheumatoid arthritis ( RA ) is an autoimmune condition , characterized by symmetrical joint inflammation , that affects approximately 1 % of the world ’s population .
3-1	16-26	Rheumatoid	object|abstract[3]	new|new[3]	appos	3-4[0_3]
3-2	27-36	arthritis	abstract[3]	new[3]	_	_
3-3	37-38	(	_	_	_	_
3-4	39-41	RA	abstract	giv	coref	3-7[5_0]
3-5	42-43	)	_	_	_	_
3-6	44-46	is	_	_	_	_
3-7	47-49	an	abstract[5]	giv[5]	coref	4-1[0_5]
3-8	50-60	autoimmune	abstract[5]	giv[5]	_	_
3-9	61-70	condition	abstract[5]	giv[5]	_	_
3-10	71-72	,	abstract[5]	giv[5]	_	_
3-11	73-86	characterized	abstract[5]	giv[5]	_	_
3-12	87-89	by	abstract[5]	giv[5]	_	_
3-13	90-101	symmetrical	abstract[5]|event[7]	giv[5]|new[7]	_	_
3-14	102-107	joint	abstract[5]|object|event[7]	giv[5]|new|new[7]	_	_
3-15	108-120	inflammation	abstract[5]|event[7]	giv[5]|new[7]	_	_
3-16	121-122	,	abstract[5]	giv[5]	_	_
3-17	123-127	that	abstract[5]	giv[5]	_	_
3-18	128-135	affects	abstract[5]	giv[5]	_	_
3-19	136-149	approximately	abstract[5]|abstract[8]	giv[5]|new[8]	_	_
3-20	150-151	1	abstract[5]|abstract[8]	giv[5]|new[8]	_	_
3-21	152-153	%	abstract[5]|abstract[8]	giv[5]|new[8]	_	_
3-22	154-156	of	abstract[5]|abstract[8]	giv[5]|new[8]	_	_
3-23	157-160	the	abstract[5]|abstract[8]|person[10]	giv[5]|new[8]|new[10]	_	_
3-24	161-166	world	abstract[5]|abstract[8]|place[9]|person[10]	giv[5]|new[8]|new[9]|new[10]	_	_
3-25	167-169	’s	abstract[5]|abstract[8]|place[9]|person[10]	giv[5]|new[8]|new[9]|new[10]	_	_
3-26	170-180	population	abstract[5]|abstract[8]|person[10]	giv[5]|new[8]|new[10]	_	_
3-27	181-182	.	_	_	_	_

#Text=RA is characterized mainly by synovium hyperplasia and a joint destruction process .
4-1	183-185	RA	abstract	giv	coref	5-24
4-2	186-188	is	_	_	_	_
4-3	189-202	characterized	_	_	_	_
4-4	203-209	mainly	_	_	_	_
4-5	210-212	by	_	_	_	_
4-6	213-221	synovium	place|abstract[13]	new|new[13]	_	_
4-7	222-233	hyperplasia	abstract[13]	new[13]	_	_
4-8	234-237	and	_	_	_	_
4-9	238-239	a	abstract[15]	new[15]	coref	8-34[52_15]
4-10	240-245	joint	event[14]|abstract[15]	new[14]|new[15]	coref	17-31[0_14]
4-11	246-257	destruction	event[14]|abstract[15]	new[14]|new[15]	_	_
4-12	258-265	process	abstract[15]	new[15]	_	_
4-13	266-267	.	_	_	_	_

#Text=In this scenario , immune cells and the inflammatory microenvironment that they create in affected joints are key components in the pathophysiology of RA .
5-1	268-270	In	_	_	_	_
5-2	271-275	this	event[16]	new[16]	_	_
5-3	276-284	scenario	event[16]	new[16]	_	_
5-4	285-286	,	_	_	_	_
5-5	287-293	immune	object[17]|abstract[18]	new[17]|new[18]	ana|coref	5-12[0_18]|15-29[117_17]
5-6	294-299	cells	object[17]|abstract[18]	new[17]|new[18]	_	_
5-7	300-303	and	abstract[18]	new[18]	_	_
5-8	304-307	the	abstract[18]|abstract[19]	new[18]|new[19]	coref	5-18[22_19]
5-9	308-320	inflammatory	abstract[18]|abstract[19]	new[18]|new[19]	_	_
5-10	321-337	microenvironment	abstract[18]|abstract[19]	new[18]|new[19]	_	_
5-11	338-342	that	abstract[18]|abstract[19]	new[18]|new[19]	_	_
5-12	343-347	they	abstract[18]|abstract[19]|abstract	new[18]|new[19]|giv	_	_
5-13	348-354	create	abstract[18]|abstract[19]	new[18]|new[19]	_	_
5-14	355-357	in	abstract[18]|abstract[19]	new[18]|new[19]	_	_
5-15	358-366	affected	abstract[18]|abstract[19]|object[21]	new[18]|new[19]|new[21]	_	_
5-16	367-373	joints	abstract[18]|abstract[19]|object[21]	new[18]|new[19]|new[21]	_	_
5-17	374-377	are	_	_	_	_
5-18	378-381	key	abstract[22]	giv[22]	_	_
5-19	382-392	components	abstract[22]	giv[22]	_	_
5-20	393-395	in	abstract[22]	giv[22]	_	_
5-21	396-399	the	abstract[22]|abstract[23]	giv[22]|new[23]	_	_
5-22	400-415	pathophysiology	abstract[22]|abstract[23]	giv[22]|new[23]	_	_
5-23	416-418	of	abstract[22]|abstract[23]	giv[22]|new[23]	_	_
5-24	419-421	RA	abstract[22]|abstract[23]|abstract	giv[22]|new[23]|giv	ana	6-3
5-25	422-423	.	_	_	_	_

#Text=Moreover , it is well-described that during the inflammatory stages of the disease , extra-articular manifestations are common , which involve other tissues or organs .
6-1	424-432	Moreover	_	_	_	_
6-2	433-434	,	_	_	_	_
6-3	435-437	it	abstract	giv	coref	7-1
6-4	438-440	is	_	_	_	_
6-5	441-455	well-described	_	_	_	_
6-6	456-460	that	_	_	_	_
6-7	461-467	during	_	_	_	_
6-8	468-471	the	abstract[26]	new[26]	_	_
6-9	472-484	inflammatory	abstract[26]	new[26]	_	_
6-10	485-491	stages	abstract[26]	new[26]	_	_
6-11	492-494	of	abstract[26]	new[26]	_	_
6-12	495-498	the	abstract[26]|abstract[27]	new[26]|new[27]	coref	8-22[0_27]
6-13	499-506	disease	abstract[26]|abstract[27]	new[26]|new[27]	_	_
6-14	507-508	,	_	_	_	_
6-15	509-524	extra-articular	event[28]	new[28]	_	_
6-16	525-539	manifestations	event[28]	new[28]	_	_
6-17	540-543	are	_	_	_	_
6-18	544-550	common	_	_	_	_
6-19	551-552	,	_	_	_	_
6-20	553-558	which	_	_	_	_
6-21	559-566	involve	_	_	_	_
6-22	567-572	other	object[29]	new[29]	coref	16-12[124_29]
6-23	573-580	tissues	object[29]	new[29]	_	_
6-24	581-583	or	_	_	_	_
6-25	584-590	organs	object	new	_	_
6-26	591-592	.	_	_	_	_

#Text=RA patients are at risk of systemic complications and several co-morbidities , including osteoporosis and frequent vertebral and hip fragility fractures .
7-1	593-595	RA	abstract|person[32]	giv|new[32]	coref|coref	8-8|8-8[43_32]
7-2	596-604	patients	person[32]	new[32]	_	_
7-3	605-608	are	_	_	_	_
7-4	609-611	at	_	_	_	_
7-5	612-616	risk	abstract[33]	new[33]	coref	8-17[45_33]
7-6	617-619	of	abstract[33]	new[33]	_	_
7-7	620-628	systemic	abstract[33]|abstract[34]	new[33]|new[34]	_	_
7-8	629-642	complications	abstract[33]|abstract[34]	new[33]|new[34]	_	_
7-9	643-646	and	abstract[33]	new[33]	_	_
7-10	647-654	several	abstract[33]|abstract[35]	new[33]|new[35]	_	_
7-11	655-669	co-morbidities	abstract[33]|abstract[35]	new[33]|new[35]	_	_
7-12	670-671	,	abstract[33]|abstract[35]	new[33]|new[35]	_	_
7-13	672-681	including	abstract[33]|abstract[35]	new[33]|new[35]	_	_
7-14	682-694	osteoporosis	abstract[33]|abstract[35]|abstract	new[33]|new[35]|new	_	_
7-15	695-698	and	abstract[33]|abstract[35]	new[33]|new[35]	_	_
7-16	699-707	frequent	abstract[33]|abstract[35]|event[38]	new[33]|new[35]|new[38]	coref	8-5[41_38]
7-17	708-717	vertebral	abstract[33]|abstract[35]|event[38]	new[33]|new[35]|new[38]	_	_
7-18	718-721	and	abstract[33]|abstract[35]|event[38]	new[33]|new[35]|new[38]	_	_
7-19	722-725	hip	abstract[33]|abstract[35]|event[38]	new[33]|new[35]|new[38]	_	_
7-20	726-735	fragility	abstract[33]|abstract[35]|abstract|event[38]	new[33]|new[35]|new|new[38]	_	_
7-21	736-745	fractures	abstract[33]|abstract[35]|event[38]	new[33]|new[35]|new[38]	_	_
7-22	746-747	.	_	_	_	_

#Text=The incidence rate of overall fractures in RA patients is 33 per 1000 person-years , and the risk is increased with disease activity and associated with overexpression of pro-inflammatory cytokines that can disturb the bone remodeling process .
8-1	748-751	The	abstract[40]	new[40]	_	_
8-2	752-761	incidence	abstract|abstract[40]	new|new[40]	_	_
8-3	762-766	rate	abstract[40]	new[40]	_	_
8-4	767-769	of	abstract[40]	new[40]	_	_
8-5	770-777	overall	abstract[40]|event[41]	new[40]|giv[41]	_	_
8-6	778-787	fractures	abstract[40]|event[41]	new[40]|giv[41]	_	_
8-7	788-790	in	abstract[40]|event[41]	new[40]|giv[41]	_	_
8-8	791-793	RA	abstract[40]|event[41]|abstract|person[43]	new[40]|giv[41]|giv|giv[43]	coref	9-24
8-9	794-802	patients	abstract[40]|event[41]|person[43]	new[40]|giv[41]|giv[43]	_	_
8-10	803-805	is	_	_	_	_
8-11	806-808	33	person[44]	new[44]	_	_
8-12	809-812	per	person[44]	new[44]	_	_
8-13	813-817	1000	person[44]	new[44]	_	_
8-14	818-830	person-years	person[44]	new[44]	_	_
8-15	831-832	,	person[44]	new[44]	_	_
8-16	833-836	and	person[44]	new[44]	_	_
8-17	837-840	the	person[44]|abstract[45]	new[44]|giv[45]	_	_
8-18	841-845	risk	person[44]|abstract[45]	new[44]|giv[45]	_	_
8-19	846-848	is	person[44]	new[44]	_	_
8-20	849-858	increased	person[44]	new[44]	_	_
8-21	859-863	with	person[44]	new[44]	_	_
8-22	864-871	disease	person[44]|abstract|abstract[47]	new[44]|giv|new[47]	coref|coref	12-11|22-12[200_47]
8-23	872-880	activity	person[44]|abstract[47]	new[44]|new[47]	_	_
8-24	881-884	and	person[44]	new[44]	_	_
8-25	885-895	associated	person[44]	new[44]	_	_
8-26	896-900	with	_	_	_	_
8-27	901-915	overexpression	event[48]	new[48]	_	_
8-28	916-918	of	event[48]	new[48]	_	_
8-29	919-935	pro-inflammatory	event[48]|substance[49]	new[48]|new[49]	coref	12-25[86_49]
8-30	936-945	cytokines	event[48]|substance[49]	new[48]|new[49]	_	_
8-31	946-950	that	event[48]|substance[49]	new[48]|new[49]	_	_
8-32	951-954	can	event[48]|substance[49]	new[48]|new[49]	_	_
8-33	955-962	disturb	event[48]|substance[49]	new[48]|new[49]	_	_
8-34	963-966	the	event[48]|substance[49]|abstract[52]	new[48]|new[49]|giv[52]	coref	9-20[59_52]
8-35	967-971	bone	event[48]|substance[49]|object|abstract[51]|abstract[52]	new[48]|new[49]|new|new[51]|giv[52]	coref	20-12
8-36	972-982	remodeling	event[48]|substance[49]|abstract[51]|abstract[52]	new[48]|new[49]|new[51]|giv[52]	_	_
8-37	983-990	process	event[48]|substance[49]|abstract[52]	new[48]|new[49]|giv[52]	_	_
8-38	991-992	.	_	_	_	_

#Text=Over the last decades , animal models — especially the rodent models — have been crucial tools for understanding the biologic process of RA , and their use can aid in developing new therapeutic strategies for fracture healing in RA inflammatory conditions .
9-1	993-997	Over	_	_	_	_
9-2	998-1001	the	time[53]	new[53]	_	_
9-3	1002-1006	last	time[53]	new[53]	_	_
9-4	1007-1014	decades	time[53]	new[53]	_	_
9-5	1015-1016	,	_	_	_	_
9-6	1017-1023	animal	animal|abstract[55]	new|new[55]	appos|coref	9-9[57_55]|10-6
9-7	1024-1030	models	abstract[55]	new[55]	_	_
9-8	1031-1032	—	_	_	_	_
9-9	1033-1043	especially	abstract[57]	giv[57]	coref	9-16[58_57]
9-10	1044-1047	the	abstract[57]	giv[57]	_	_
9-11	1048-1054	rodent	animal|abstract[57]	new|giv[57]	_	_
9-12	1055-1061	models	abstract[57]	giv[57]	_	_
9-13	1062-1063	—	_	_	_	_
9-14	1064-1068	have	_	_	_	_
9-15	1069-1073	been	_	_	_	_
9-16	1074-1081	crucial	abstract[58]	giv[58]	ana	9-27[0_58]
9-17	1082-1087	tools	abstract[58]	giv[58]	_	_
9-18	1088-1091	for	abstract[58]	giv[58]	_	_
9-19	1092-1105	understanding	abstract[58]	giv[58]	_	_
9-20	1106-1109	the	abstract[58]|abstract[59]	giv[58]|giv[59]	coref	12-43[92_59]
9-21	1110-1118	biologic	abstract[58]|abstract[59]	giv[58]|giv[59]	_	_
9-22	1119-1126	process	abstract[58]|abstract[59]	giv[58]|giv[59]	_	_
9-23	1127-1129	of	abstract[58]|abstract[59]	giv[58]|giv[59]	_	_
9-24	1130-1132	RA	abstract[58]|abstract[59]|abstract	giv[58]|giv[59]|giv	coref	10-18
9-25	1133-1134	,	_	_	_	_
9-26	1135-1138	and	_	_	_	_
9-27	1139-1144	their	abstract|abstract[62]	giv|new[62]	coref|coref	10-1[71_0]|18-6[146_62]
9-28	1145-1148	use	abstract[62]	new[62]	_	_
9-29	1149-1152	can	_	_	_	_
9-30	1153-1156	aid	_	_	_	_
9-31	1157-1159	in	_	_	_	_
9-32	1160-1170	developing	_	_	_	_
9-33	1171-1174	new	abstract[63]	new[63]	coref	12-49[93_63]
9-34	1175-1186	therapeutic	abstract[63]	new[63]	_	_
9-35	1187-1197	strategies	abstract[63]	new[63]	_	_
9-36	1198-1201	for	abstract[63]	new[63]	_	_
9-37	1202-1210	fracture	abstract[63]|abstract|event[65]	new[63]|new|new[65]	_	_
9-38	1211-1218	healing	abstract[63]|event[65]	new[63]|new[65]	_	_
9-39	1219-1221	in	abstract[63]|event[65]	new[63]|new[65]	_	_
9-40	1222-1224	RA	abstract[63]|event[65]|abstract[66]	new[63]|new[65]|new[66]	coref	18-29[156_66]
9-41	1225-1237	inflammatory	abstract[63]|event[65]|abstract[66]	new[63]|new[65]|new[66]	_	_
9-42	1238-1248	conditions	abstract[63]|event[65]|abstract[66]	new[63]|new[65]|new[66]	_	_
9-43	1249-1250	.	_	_	_	_

#Text=Collagen induced-arthritis ( CIA ) animal models have been one of the most widely used models in RA research .
10-1	1251-1259	Collagen	organization|object[68]|abstract[71]	new|new[68]|giv[71]	coref	10-12[73_71]
10-2	1260-1277	induced-arthritis	object[68]|abstract[71]	new[68]|giv[71]	_	_
10-3	1278-1279	(	abstract[71]	giv[71]	_	_
10-4	1280-1283	CIA	organization|abstract[71]	new|giv[71]	coref	11-6
10-5	1284-1285	)	abstract[71]	giv[71]	_	_
10-6	1286-1292	animal	animal|abstract[71]	giv|giv[71]	coref	11-10
10-7	1293-1299	models	abstract[71]	giv[71]	_	_
10-8	1300-1304	have	_	_	_	_
10-9	1305-1309	been	_	_	_	_
10-10	1310-1313	one	abstract[72]	new[72]	_	_
10-11	1314-1316	of	abstract[72]	new[72]	_	_
10-12	1317-1320	the	abstract[72]|abstract[73]	new[72]|giv[73]	coref	21-9[178_73]
10-13	1321-1325	most	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-14	1326-1332	widely	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-15	1333-1337	used	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-16	1338-1344	models	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-17	1345-1347	in	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-18	1348-1350	RA	abstract[72]|abstract[73]|abstract|abstract[75]	new[72]|giv[73]|giv|new[75]	coref	11-14
10-19	1351-1359	research	abstract[72]|abstract[73]|abstract[75]	new[72]|giv[73]|new[75]	_	_
10-20	1360-1361	.	_	_	_	_

#Text=Originally described by Trentham , CIA is a reproducible animal experimental model of RA .
11-1	1362-1372	Originally	organization[79]	giv[79]	coref|ana	11-1[79_0]|12-37[0_79]
11-2	1373-1382	described	organization[79]	giv[79]	_	_
11-3	1383-1385	by	organization[79]	giv[79]	_	_
11-4	1386-1394	Trentham	person|organization[79]	new|giv[79]	_	_
11-5	1395-1396	,	organization[79]	giv[79]	_	_
11-6	1397-1400	CIA	organization|organization[79]	giv|giv[79]	_	_
11-7	1401-1403	is	organization[79]	giv[79]	_	_
11-8	1404-1405	a	organization[79]	giv[79]	_	_
11-9	1406-1418	reproducible	organization[79]	giv[79]	_	_
11-10	1419-1425	animal	animal|organization[79]	giv|giv[79]	_	_
11-11	1426-1438	experimental	organization[79]	giv[79]	_	_
11-12	1439-1444	model	organization[79]	giv[79]	_	_
11-13	1445-1447	of	organization[79]	giv[79]	_	_
11-14	1448-1450	RA	organization[79]|abstract	giv[79]|giv	coref	12-7[82_0]
11-15	1451-1452	.	_	_	_	_

#Text=In fact , the similarity to human RA regarding the disease clinical , histological , and immunological signals — including high articular levels of inflammatory cytokines — like tumor necrosis factor-α ( TNF-α ) , make it an invaluable model to study the pathologic process and to search new therapeutic strategies .
12-1	1453-1455	In	_	_	_	_
12-2	1456-1460	fact	_	_	_	_
12-3	1461-1462	,	_	_	_	_
12-4	1463-1466	the	abstract[81]	new[81]	_	_
12-5	1467-1477	similarity	abstract[81]	new[81]	_	_
12-6	1478-1480	to	abstract[81]	new[81]	_	_
12-7	1481-1486	human	abstract[81]|abstract[82]	new[81]|giv[82]	coref	15-4[0_82]
12-8	1487-1489	RA	abstract[81]|abstract[82]	new[81]|giv[82]	_	_
12-9	1490-1499	regarding	abstract[81]	new[81]	_	_
12-10	1500-1503	the	abstract[81]|abstract[84]	new[81]|new[84]	_	_
12-11	1504-1511	disease	abstract[81]|abstract|abstract[84]	new[81]|giv|new[84]	_	_
12-12	1512-1520	clinical	abstract[81]|abstract[84]	new[81]|new[84]	_	_
12-13	1521-1522	,	abstract[81]|abstract[84]	new[81]|new[84]	_	_
12-14	1523-1535	histological	abstract[81]|abstract[84]	new[81]|new[84]	_	_
12-15	1536-1537	,	abstract[81]|abstract[84]	new[81]|new[84]	_	_
12-16	1538-1541	and	abstract[81]|abstract[84]	new[81]|new[84]	_	_
12-17	1542-1555	immunological	abstract[81]|abstract[84]	new[81]|new[84]	_	_
12-18	1556-1563	signals	abstract[81]|abstract[84]	new[81]|new[84]	_	_
12-19	1564-1565	—	abstract[81]|abstract[84]	new[81]|new[84]	_	_
12-20	1566-1575	including	abstract[81]|abstract[84]	new[81]|new[84]	_	_
12-21	1576-1580	high	abstract[81]|abstract[84]|abstract[85]	new[81]|new[84]|new[85]	_	_
12-22	1581-1590	articular	abstract[81]|abstract[84]|abstract[85]	new[81]|new[84]|new[85]	_	_
12-23	1591-1597	levels	abstract[81]|abstract[84]|abstract[85]	new[81]|new[84]|new[85]	_	_
12-24	1598-1600	of	abstract[81]|abstract[84]|abstract[85]	new[81]|new[84]|new[85]	_	_
12-25	1601-1613	inflammatory	abstract[81]|abstract[84]|abstract[85]|substance[86]	new[81]|new[84]|new[85]|giv[86]	_	_
12-26	1614-1623	cytokines	abstract[81]|abstract[84]|abstract[85]|substance[86]	new[81]|new[84]|new[85]|giv[86]	_	_
12-27	1624-1625	—	abstract[81]|abstract[84]|abstract[85]	new[81]|new[84]|new[85]	_	_
12-28	1626-1630	like	abstract[81]|abstract[84]|abstract[85]	new[81]|new[84]|new[85]	_	_
12-29	1631-1636	tumor	abstract[81]|abstract[84]|abstract[85]|object|abstract[89]	new[81]|new[84]|new[85]|new|new[89]	appos	12-33[0_89]
12-30	1637-1645	necrosis	abstract[81]|abstract[84]|abstract[85]|abstract|abstract[89]	new[81]|new[84]|new[85]|new|new[89]	_	_
12-31	1646-1654	factor-α	abstract[81]|abstract[84]|abstract[85]|abstract[89]	new[81]|new[84]|new[85]|new[89]	_	_
12-32	1655-1656	(	_	_	_	_
12-33	1657-1662	TNF-α	abstract	giv	coref	13-22
12-34	1663-1664	)	_	_	_	_
12-35	1665-1666	,	_	_	_	_
12-36	1667-1671	make	_	_	_	_
12-37	1672-1674	it	organization	giv	coref	13-4[96_0]
12-38	1675-1677	an	_	_	_	_
12-39	1678-1688	invaluable	_	_	_	_
12-40	1689-1694	model	_	_	_	_
12-41	1695-1697	to	_	_	_	_
12-42	1698-1703	study	_	_	_	_
12-43	1704-1707	the	abstract[92]	giv[92]	_	_
12-44	1708-1718	pathologic	abstract[92]	giv[92]	_	_
12-45	1719-1726	process	abstract[92]	giv[92]	_	_
12-46	1727-1730	and	_	_	_	_
12-47	1731-1733	to	_	_	_	_
12-48	1734-1740	search	_	_	_	_
12-49	1741-1744	new	abstract[93]	giv[93]	_	_
12-50	1745-1756	therapeutic	abstract[93]	giv[93]	_	_
12-51	1757-1767	strategies	abstract[93]	giv[93]	_	_
12-52	1768-1769	.	_	_	_	_

#Text=The response to rat CIA has been reported to involve macrophages , T and B lymphocytes , and mediators such as TNF-α , Interleukin ( IL)-1β , IL-6 , and IL-17 .
13-1	1770-1773	The	abstract[94]	new[94]	coref	14-3[107_94]
13-2	1774-1782	response	abstract[94]	new[94]	_	_
13-3	1783-1785	to	abstract[94]	new[94]	_	_
13-4	1786-1789	rat	abstract[94]|animal|organization[96]	new[94]|new|giv[96]	coref	14-7[108_96]
13-5	1790-1793	CIA	abstract[94]|organization[96]	new[94]|giv[96]	_	_
13-6	1794-1797	has	_	_	_	_
13-7	1798-1802	been	_	_	_	_
13-8	1803-1811	reported	_	_	_	_
13-9	1812-1814	to	_	_	_	_
13-10	1815-1822	involve	_	_	_	_
13-11	1823-1834	macrophages	animal	new	_	_
13-12	1835-1836	,	_	_	_	_
13-13	1837-1838	T	person|plant[100]	new|new[100]	_	_
13-14	1839-1842	and	plant[100]	new[100]	_	_
13-15	1843-1844	B	place|plant[100]	new|new[100]	_	_
13-16	1845-1856	lymphocytes	plant[100]	new[100]	_	_
13-17	1857-1858	,	_	_	_	_
13-18	1859-1862	and	_	_	_	_
13-19	1863-1872	mediators	person[101]	new[101]	_	_
13-20	1873-1877	such	person[101]	new[101]	_	_
13-21	1878-1880	as	person[101]	new[101]	_	_
13-22	1881-1886	TNF-α	person[101]|abstract	new[101]|giv	_	_
13-23	1887-1888	,	person[101]	new[101]	_	_
13-24	1889-1900	Interleukin	person[101]|abstract	new[101]|new	_	_
13-25	1901-1902	(	person[101]	new[101]	_	_
13-26	1903-1909	IL)-1β	person[101]|abstract	new[101]|new	_	_
13-27	1910-1911	,	person[101]	new[101]	_	_
13-28	1912-1916	IL-6	person[101]|abstract	new[101]|new	coref	21-53
13-29	1917-1918	,	person[101]	new[101]	_	_
13-30	1919-1922	and	person[101]	new[101]	_	_
13-31	1923-1928	IL-17	person[101]|abstract	new[101]|new	_	_
13-32	1929-1930	.	_	_	_	_

#Text=Nonetheless , the systemic response in this model has not been well characterized so far .
14-1	1931-1942	Nonetheless	_	_	_	_
14-2	1943-1944	,	_	_	_	_
14-3	1945-1948	the	abstract[107]	giv[107]	_	_
14-4	1949-1957	systemic	abstract[107]	giv[107]	_	_
14-5	1958-1966	response	abstract[107]	giv[107]	_	_
14-6	1967-1969	in	abstract[107]	giv[107]	_	_
14-7	1970-1974	this	abstract[107]|organization[108]	giv[107]|giv[108]	coref	17-15[0_108]
14-8	1975-1980	model	abstract[107]|organization[108]	giv[107]|giv[108]	_	_
14-9	1981-1984	has	_	_	_	_
14-10	1985-1988	not	_	_	_	_
14-11	1989-1993	been	_	_	_	_
14-12	1994-1998	well	_	_	_	_
14-13	1999-2012	characterized	_	_	_	_
14-14	2013-2015	so	_	_	_	_
14-15	2016-2019	far	_	_	_	_
14-16	2020-2021	.	_	_	_	_

#Text=Importantly , current RA treatments do not promote joint repair , and several efforts are being made to develop new therapies , especially based in cell approaches using mesenchymal stem/stromal cells ( MSC ) .
15-1	2022-2033	Importantly	_	_	_	_
15-2	2034-2035	,	_	_	_	_
15-3	2036-2043	current	abstract[110]	new[110]	_	_
15-4	2044-2046	RA	abstract|abstract[110]	giv|new[110]	coref	17-12
15-5	2047-2057	treatments	abstract[110]	new[110]	_	_
15-6	2058-2060	do	_	_	_	_
15-7	2061-2064	not	_	_	_	_
15-8	2065-2072	promote	_	_	_	_
15-9	2073-2078	joint	event[111]	new[111]	coref	16-42[134_111]
15-10	2079-2085	repair	event[111]	new[111]	_	_
15-11	2086-2087	,	_	_	_	_
15-12	2088-2091	and	_	_	_	_
15-13	2092-2099	several	event[112]	new[112]	_	_
15-14	2100-2107	efforts	event[112]	new[112]	_	_
15-15	2108-2111	are	_	_	_	_
15-16	2112-2117	being	_	_	_	_
15-17	2118-2122	made	_	_	_	_
15-18	2123-2125	to	_	_	_	_
15-19	2126-2133	develop	_	_	_	_
15-20	2134-2137	new	abstract[113]	new[113]	_	_
15-21	2138-2147	therapies	abstract[113]	new[113]	_	_
15-22	2148-2149	,	abstract[113]	new[113]	_	_
15-23	2150-2160	especially	abstract[113]	new[113]	_	_
15-24	2161-2166	based	abstract[113]	new[113]	_	_
15-25	2167-2169	in	abstract[113]	new[113]	_	_
15-26	2170-2174	cell	abstract[113]|place|abstract[115]	new[113]|new|new[115]	coref	16-38
15-27	2175-2185	approaches	abstract[113]|abstract[115]	new[113]|new[115]	_	_
15-28	2186-2191	using	abstract[113]|abstract[115]	new[113]|new[115]	_	_
15-29	2192-2203	mesenchymal	abstract[113]|abstract[115]|object[117]	new[113]|new[115]|giv[117]	_	_
15-30	2204-2216	stem/stromal	abstract[113]|abstract[115]|substance|object[117]	new[113]|new[115]|new|giv[117]	_	_
15-31	2217-2222	cells	abstract[113]|abstract[115]|object[117]	new[113]|new[115]|giv[117]	_	_
15-32	2223-2224	(	_	_	_	_
15-33	2225-2228	MSC	abstract	new	coref	16-1
15-34	2229-2230	)	_	_	_	_
15-35	2231-2232	.	_	_	_	_

#Text=MSC are multipotent progenitor cells with the potential to differentiate into mesenchymal lineage tissues ( e.g. , bone , cartilage , and adipose tissue ) , described to have immunomodulatory roles , being capable of recruiting different cell types and promoting tissue repair .
16-1	2233-2236	MSC	abstract	giv	coref	16-3[121_0]
16-2	2237-2240	are	_	_	_	_
16-3	2241-2252	multipotent	abstract[121]	giv[121]	coref	17-4[0_121]
16-4	2253-2263	progenitor	object|abstract[121]	new|giv[121]	_	_
16-5	2264-2269	cells	abstract[121]	giv[121]	_	_
16-6	2270-2274	with	abstract[121]	giv[121]	_	_
16-7	2275-2278	the	abstract[121]|abstract[122]	giv[121]|new[122]	_	_
16-8	2279-2288	potential	abstract[121]|abstract[122]	giv[121]|new[122]	_	_
16-9	2289-2291	to	abstract[121]|abstract[122]	giv[121]|new[122]	_	_
16-10	2292-2305	differentiate	abstract[121]|abstract[122]	giv[121]|new[122]	_	_
16-11	2306-2310	into	abstract[121]|abstract[122]	giv[121]|new[122]	_	_
16-12	2311-2322	mesenchymal	abstract[121]|abstract[122]|object[124]	giv[121]|new[122]|giv[124]	appos	16-16[125_124]
16-13	2323-2330	lineage	abstract[121]|abstract[122]|abstract|object[124]	giv[121]|new[122]|new|giv[124]	_	_
16-14	2331-2338	tissues	abstract[121]|abstract[122]|object[124]	giv[121]|new[122]|giv[124]	_	_
16-15	2339-2340	(	abstract[121]	giv[121]	_	_
16-16	2341-2345	e.g.	abstract[121]|object[125]|object[126]	giv[121]|giv[125]|giv[126]	appos|appos	16-16[126_125]|16-20[0_126]
16-17	2346-2347	,	abstract[121]|object[125]|object[126]	giv[121]|giv[125]|giv[126]	_	_
16-18	2348-2352	bone	abstract[121]|object[125]|object[126]	giv[121]|giv[125]|giv[126]	_	_
16-19	2353-2354	,	abstract[121]|object[126]	giv[121]|giv[126]	_	_
16-20	2355-2364	cartilage	abstract[121]|object[126]|object	giv[121]|giv[126]|giv	appos	16-23[129_0]
16-21	2365-2366	,	abstract[121]|object[126]	giv[121]|giv[126]	_	_
16-22	2367-2370	and	abstract[121]|object[126]	giv[121]|giv[126]	_	_
16-23	2371-2378	adipose	abstract[121]|object[126]|abstract|object[129]	giv[121]|giv[126]|new|giv[129]	_	_
16-24	2379-2385	tissue	abstract[121]|object[126]|object[129]	giv[121]|giv[126]|giv[129]	_	_
16-25	2386-2387	)	abstract[121]	giv[121]	_	_
16-26	2388-2389	,	abstract[121]	giv[121]	_	_
16-27	2390-2399	described	abstract[121]	giv[121]	_	_
16-28	2400-2402	to	abstract[121]	giv[121]	_	_
16-29	2403-2407	have	abstract[121]	giv[121]	_	_
16-30	2408-2424	immunomodulatory	abstract[121]|abstract[130]	giv[121]|new[130]	_	_
16-31	2425-2430	roles	abstract[121]|abstract[130]	giv[121]|new[130]	_	_
16-32	2431-2432	,	_	_	_	_
16-33	2433-2438	being	_	_	_	_
16-34	2439-2446	capable	_	_	_	_
16-35	2447-2449	of	_	_	_	_
16-36	2450-2460	recruiting	_	_	_	_
16-37	2461-2470	different	abstract[132]	new[132]	_	_
16-38	2471-2475	cell	place|abstract[132]	giv|new[132]	_	_
16-39	2476-2481	types	abstract[132]	new[132]	_	_
16-40	2482-2485	and	_	_	_	_
16-41	2486-2495	promoting	_	_	_	_
16-42	2496-2502	tissue	object|event[134]	new|giv[134]	_	_
16-43	2503-2509	repair	event[134]	giv[134]	_	_
16-44	2510-2511	.	_	_	_	_

#Text=The transplantation of MSC has been reported to ameliorate or delay RA onset in CIA animals , partially mediated by inflammatory signaling suppression , and thereby reducing joint swelling and destruction .
17-1	2512-2515	The	event[135]	new[135]	coref	18-9[148_135]
17-2	2516-2531	transplantation	event[135]	new[135]	_	_
17-3	2532-2534	of	event[135]	new[135]	_	_
17-4	2535-2538	MSC	event[135]|abstract	new[135]|giv	coref	18-9
17-5	2539-2542	has	_	_	_	_
17-6	2543-2547	been	_	_	_	_
17-7	2548-2556	reported	_	_	_	_
17-8	2557-2559	to	_	_	_	_
17-9	2560-2570	ameliorate	_	_	_	_
17-10	2571-2573	or	_	_	_	_
17-11	2574-2579	delay	_	_	_	_
17-12	2580-2582	RA	abstract|event[138]	giv|new[138]	coref	19-6[158_0]
17-13	2583-2588	onset	event[138]	new[138]	_	_
17-14	2589-2591	in	_	_	_	_
17-15	2592-2595	CIA	organization|animal[140]	giv|new[140]	coref|coref	18-16|18-16[151_140]
17-16	2596-2603	animals	animal[140]	new[140]	_	_
17-17	2604-2605	,	_	_	_	_
17-18	2606-2615	partially	_	_	_	_
17-19	2616-2624	mediated	_	_	_	_
17-20	2625-2627	by	_	_	_	_
17-21	2628-2640	inflammatory	abstract[142]	new[142]	_	_
17-22	2641-2650	signaling	abstract|abstract[142]	new|new[142]	_	_
17-23	2651-2662	suppression	abstract[142]	new[142]	_	_
17-24	2663-2664	,	_	_	_	_
17-25	2665-2668	and	_	_	_	_
17-26	2669-2676	thereby	_	_	_	_
17-27	2677-2685	reducing	_	_	_	_
17-28	2686-2691	joint	event[143]	new[143]	_	_
17-29	2692-2700	swelling	event[143]	new[143]	_	_
17-30	2701-2704	and	_	_	_	_
17-31	2705-2716	destruction	event	giv	_	_
17-32	2717-2718	.	_	_	_	_

#Text=Although the available evidence supports the use of MSC transplantation as a cell-based strategy in CIA animals , data on the biology of endogenous CIA animals-derived MSC in basal conditions is scarce .
18-1	2719-2727	Although	_	_	_	_
18-2	2728-2731	the	abstract[145]	new[145]	_	_
18-3	2732-2741	available	abstract[145]	new[145]	_	_
18-4	2742-2750	evidence	abstract[145]	new[145]	_	_
18-5	2751-2759	supports	_	_	_	_
18-6	2760-2763	the	abstract[146]	giv[146]	_	_
18-7	2764-2767	use	abstract[146]	giv[146]	_	_
18-8	2768-2770	of	abstract[146]	giv[146]	_	_
18-9	2771-2774	MSC	abstract[146]|abstract|event[148]	giv[146]|giv|giv[148]	coref	18-24[155_0]
18-10	2775-2790	transplantation	abstract[146]|event[148]	giv[146]|giv[148]	_	_
18-11	2791-2793	as	abstract[146]|event[148]	giv[146]|giv[148]	_	_
18-12	2794-2795	a	abstract[146]|event[148]|abstract[149]	giv[146]|giv[148]|new[149]	_	_
18-13	2796-2806	cell-based	abstract[146]|event[148]|abstract[149]	giv[146]|giv[148]|new[149]	_	_
18-14	2807-2815	strategy	abstract[146]|event[148]|abstract[149]	giv[146]|giv[148]|new[149]	_	_
18-15	2816-2818	in	abstract[146]|event[148]|abstract[149]	giv[146]|giv[148]|new[149]	_	_
18-16	2819-2822	CIA	abstract[146]|event[148]|abstract[149]|organization|animal[151]	giv[146]|giv[148]|new[149]|giv|giv[151]	coref|coref	18-25|21-16[180_151]
18-17	2823-2830	animals	abstract[146]|event[148]|abstract[149]|animal[151]	giv[146]|giv[148]|new[149]|giv[151]	_	_
18-18	2831-2832	,	_	_	_	_
18-19	2833-2837	data	abstract[152]	new[152]	_	_
18-20	2838-2840	on	abstract[152]	new[152]	_	_
18-21	2841-2844	the	abstract[152]|abstract[153]	new[152]|new[153]	_	_
18-22	2845-2852	biology	abstract[152]|abstract[153]	new[152]|new[153]	_	_
18-23	2853-2855	of	abstract[152]|abstract[153]	new[152]|new[153]	_	_
18-24	2856-2866	endogenous	abstract[152]|abstract[153]|abstract[155]	new[152]|new[153]|giv[155]	coref	19-14[160_155]
18-25	2867-2870	CIA	abstract[152]|abstract[153]|organization|abstract[155]	new[152]|new[153]|giv|giv[155]	coref	20-5
18-26	2871-2886	animals-derived	abstract[152]|abstract[153]|abstract[155]	new[152]|new[153]|giv[155]	_	_
18-27	2887-2890	MSC	abstract[152]|abstract[153]|abstract[155]	new[152]|new[153]|giv[155]	_	_
18-28	2891-2893	in	abstract[152]|abstract[153]|abstract[155]	new[152]|new[153]|giv[155]	_	_
18-29	2894-2899	basal	abstract[152]|abstract[153]|abstract[155]|abstract[156]	new[152]|new[153]|giv[155]|giv[156]	coref	20-15[166_156]
18-30	2900-2910	conditions	abstract[152]|abstract[153]|abstract[155]|abstract[156]	new[152]|new[153]|giv[155]|giv[156]	_	_
18-31	2911-2913	is	_	_	_	_
18-32	2914-2920	scarce	_	_	_	_
18-33	2921-2922	.	_	_	_	_

#Text=Moreover , the impact of the systemic inflammatory condition on biological properties of endogenous MSC has not been explored yet .
19-1	2923-2931	Moreover	_	_	_	_
19-2	2932-2933	,	_	_	_	_
19-3	2934-2937	the	abstract[157]	new[157]	_	_
19-4	2938-2944	impact	abstract[157]	new[157]	_	_
19-5	2945-2947	of	abstract[157]	new[157]	_	_
19-6	2948-2951	the	abstract[157]|abstract[158]	new[157]|giv[158]	coref	20-25[0_158]
19-7	2952-2960	systemic	abstract[157]|abstract[158]	new[157]|giv[158]	_	_
19-8	2961-2973	inflammatory	abstract[157]|abstract[158]	new[157]|giv[158]	_	_
19-9	2974-2983	condition	abstract[157]|abstract[158]	new[157]|giv[158]	_	_
19-10	2984-2986	on	abstract[157]	new[157]	_	_
19-11	2987-2997	biological	abstract[157]|abstract[159]	new[157]|new[159]	_	_
19-12	2998-3008	properties	abstract[157]|abstract[159]	new[157]|new[159]	_	_
19-13	3009-3011	of	abstract[157]|abstract[159]	new[157]|new[159]	_	_
19-14	3012-3022	endogenous	abstract[157]|abstract[159]|abstract[160]	new[157]|new[159]|giv[160]	coref	20-32[172_160]
19-15	3023-3026	MSC	abstract[157]|abstract[159]|abstract[160]	new[157]|new[159]|giv[160]	_	_
19-16	3027-3030	has	_	_	_	_
19-17	3031-3034	not	_	_	_	_
19-18	3035-3039	been	_	_	_	_
19-19	3040-3048	explored	_	_	_	_
19-20	3049-3052	yet	_	_	_	_
19-21	3053-3054	.	_	_	_	_

#Text=Herein , we propose CIA as a reliable model to study bone regeneration in inflammatory conditions , and additionally we investigate the effect of RA induction on the biological behavior of endogenous MSC as crucial cells involved in repair/regeneration .
20-1	3055-3061	Herein	_	_	_	_
20-2	3062-3063	,	_	_	_	_
20-3	3064-3066	we	person	acc	ana	20-20
20-4	3067-3074	propose	_	_	_	_
20-5	3075-3078	CIA	organization	giv	coref	20-7[163_0]
20-6	3079-3081	as	_	_	_	_
20-7	3082-3083	a	organization[163]	giv[163]	coref	21-16[0_163]
20-8	3084-3092	reliable	organization[163]	giv[163]	_	_
20-9	3093-3098	model	organization[163]	giv[163]	_	_
20-10	3099-3101	to	organization[163]	giv[163]	_	_
20-11	3102-3107	study	organization[163]	giv[163]	_	_
20-12	3108-3112	bone	organization[163]|object|event[165]	giv[163]|giv|new[165]	coref	21-21
20-13	3113-3125	regeneration	organization[163]|event[165]	giv[163]|new[165]	_	_
20-14	3126-3128	in	organization[163]	giv[163]	_	_
20-15	3129-3141	inflammatory	organization[163]|abstract[166]	giv[163]|giv[166]	coref	22-57[215_166]
20-16	3142-3152	conditions	organization[163]|abstract[166]	giv[163]|giv[166]	_	_
20-17	3153-3154	,	_	_	_	_
20-18	3155-3158	and	_	_	_	_
20-19	3159-3171	additionally	_	_	_	_
20-20	3172-3174	we	person	giv	ana	21-1
20-21	3175-3186	investigate	_	_	_	_
20-22	3187-3190	the	abstract[168]	new[168]	_	_
20-23	3191-3197	effect	abstract[168]	new[168]	_	_
20-24	3198-3200	of	abstract[168]	new[168]	_	_
20-25	3201-3203	RA	abstract[168]|abstract|abstract[170]	new[168]|giv|new[170]	coref|coref	22-8|22-7[199_170]
20-26	3204-3213	induction	abstract[168]|abstract[170]	new[168]|new[170]	_	_
20-27	3214-3216	on	abstract[168]	new[168]	_	_
20-28	3217-3220	the	abstract[168]|abstract[171]	new[168]|new[171]	_	_
20-29	3221-3231	biological	abstract[168]|abstract[171]	new[168]|new[171]	_	_
20-30	3232-3240	behavior	abstract[168]|abstract[171]	new[168]|new[171]	_	_
20-31	3241-3243	of	abstract[168]|abstract[171]	new[168]|new[171]	_	_
20-32	3244-3254	endogenous	abstract[168]|abstract[171]|abstract[172]	new[168]|new[171]|giv[172]	coref	20-35[173_172]
20-33	3255-3258	MSC	abstract[168]|abstract[171]|abstract[172]	new[168]|new[171]|giv[172]	_	_
20-34	3259-3261	as	abstract[168]|abstract[171]|abstract[172]	new[168]|new[171]|giv[172]	_	_
20-35	3262-3269	crucial	abstract[168]|abstract[171]|abstract[172]|abstract[173]	new[168]|new[171]|giv[172]|giv[173]	coref	21-29[185_173]
20-36	3270-3275	cells	abstract[168]|abstract[171]|abstract[172]|abstract[173]	new[168]|new[171]|giv[172]|giv[173]	_	_
20-37	3276-3284	involved	abstract[168]|abstract[171]|abstract[172]|abstract[173]	new[168]|new[171]|giv[172]|giv[173]	_	_
20-38	3285-3287	in	abstract[168]|abstract[171]|abstract[172]|abstract[173]	new[168]|new[171]|giv[172]|giv[173]	_	_
20-39	3288-3307	repair/regeneration	abstract[168]|abstract[171]|abstract[172]|abstract[173]|event	new[168]|new[171]|giv[172]|giv[173]|new	_	_
20-40	3308-3309	.	_	_	_	_

#Text=Our results have shown that the combination of the two models is feasible and that CIA animals respond to the bone injury with a significant increase of systemic myeloid cells number and their co-stimulatory molecules ( CD40 and CD86 ) expression , accompanied by increased levels of IL-13 , IL-2 , and IL-6 in plasma .
21-1	3310-3313	Our	person|abstract[176]	giv|new[176]	_	_
21-2	3314-3321	results	abstract[176]	new[176]	_	_
21-3	3322-3326	have	_	_	_	_
21-4	3327-3332	shown	_	_	_	_
21-5	3333-3337	that	_	_	_	_
21-6	3338-3341	the	abstract[177]	new[177]	_	_
21-7	3342-3353	combination	abstract[177]	new[177]	_	_
21-8	3354-3356	of	abstract[177]	new[177]	_	_
21-9	3357-3360	the	abstract[177]|abstract[178]	new[177]|giv[178]	_	_
21-10	3361-3364	two	abstract[177]|abstract[178]	new[177]|giv[178]	_	_
21-11	3365-3371	models	abstract[177]|abstract[178]	new[177]|giv[178]	_	_
21-12	3372-3374	is	_	_	_	_
21-13	3375-3383	feasible	_	_	_	_
21-14	3384-3387	and	_	_	_	_
21-15	3388-3392	that	_	_	_	_
21-16	3393-3396	CIA	organization|animal[180]	giv|giv[180]	ana	21-33[0_180]
21-17	3397-3404	animals	animal[180]	giv[180]	_	_
21-18	3405-3412	respond	_	_	_	_
21-19	3413-3415	to	_	_	_	_
21-20	3416-3419	the	event[182]	new[182]	_	_
21-21	3420-3424	bone	object|event[182]	giv|new[182]	_	_
21-22	3425-3431	injury	event[182]	new[182]	_	_
21-23	3432-3436	with	_	_	_	_
21-24	3437-3438	a	event[183]	new[183]	_	_
21-25	3439-3450	significant	event[183]	new[183]	_	_
21-26	3451-3459	increase	event[183]	new[183]	_	_
21-27	3460-3462	of	event[183]	new[183]	_	_
21-28	3463-3471	systemic	event[183]|abstract[186]	new[183]|new[186]	_	_
21-29	3472-3479	myeloid	event[183]|object|abstract[185]|abstract[186]	new[183]|new|giv[185]|new[186]	coref	22-18[203_185]
21-30	3480-3485	cells	event[183]|abstract[185]|abstract[186]	new[183]|giv[185]|new[186]	_	_
21-31	3486-3492	number	event[183]|abstract[186]	new[183]|new[186]	_	_
21-32	3493-3496	and	event[183]	new[183]	_	_
21-33	3497-3502	their	event[183]|animal|object[188]	new[183]|giv|new[188]	_	_
21-34	3503-3517	co-stimulatory	event[183]|object[188]	new[183]|new[188]	_	_
21-35	3518-3527	molecules	event[183]|object[188]	new[183]|new[188]	_	_
21-36	3528-3529	(	_	_	_	_
21-37	3530-3534	CD40	abstract	new	_	_
21-38	3535-3538	and	_	_	_	_
21-39	3539-3543	CD86	abstract	new	_	_
21-40	3544-3545	)	_	_	_	_
21-41	3546-3556	expression	abstract	new	coref	22-27[206_0]
21-42	3557-3558	,	_	_	_	_
21-43	3559-3570	accompanied	_	_	_	_
21-44	3571-3573	by	_	_	_	_
21-45	3574-3583	increased	abstract[192]	new[192]	_	_
21-46	3584-3590	levels	abstract[192]	new[192]	_	_
21-47	3591-3593	of	abstract[192]	new[192]	_	_
21-48	3594-3599	IL-13	abstract[192]|abstract	new[192]|new	_	_
21-49	3600-3601	,	abstract[192]	new[192]	_	_
21-50	3602-3606	IL-2	abstract[192]|abstract	new[192]|new	_	_
21-51	3607-3608	,	abstract[192]	new[192]	_	_
21-52	3609-3612	and	abstract[192]	new[192]	_	_
21-53	3613-3617	IL-6	abstract[192]|abstract	new[192]|giv	_	_
21-54	3618-3620	in	abstract[192]	new[192]	_	_
21-55	3621-3627	plasma	abstract[192]|substance	new[192]|new	_	_
21-56	3628-3629	.	_	_	_	_

#Text=The systemic inflammatory environment created by the arthritis induction leads to decreased metabolic activity and proliferation of CIA-derived MSC , and increased differentiation capacity determined by the expression of osteogenic ( runt-related transcription factor 2 ( RUNX2 ) and alkaline phosphatase ( ALP ) ) , and chondrogenic ( aggrecan ( ACAN ) ) markers in basal conditions .
22-1	3630-3633	The	abstract[197]	new[197]	_	_
22-2	3634-3642	systemic	abstract[197]	new[197]	_	_
22-3	3643-3655	inflammatory	abstract[197]	new[197]	_	_
22-4	3656-3667	environment	abstract[197]	new[197]	_	_
22-5	3668-3675	created	abstract[197]	new[197]	_	_
22-6	3676-3678	by	abstract[197]	new[197]	_	_
22-7	3679-3682	the	abstract[197]|abstract[199]	new[197]|giv[199]	_	_
22-8	3683-3692	arthritis	abstract[197]|abstract|abstract[199]	new[197]|giv|giv[199]	_	_
22-9	3693-3702	induction	abstract[197]|abstract[199]	new[197]|giv[199]	_	_
22-10	3703-3708	leads	_	_	_	_
22-11	3709-3711	to	_	_	_	_
22-12	3712-3721	decreased	abstract[200]	giv[200]	_	_
22-13	3722-3731	metabolic	abstract[200]	giv[200]	_	_
22-14	3732-3740	activity	abstract[200]	giv[200]	_	_
22-15	3741-3744	and	_	_	_	_
22-16	3745-3758	proliferation	event[201]	new[201]	_	_
22-17	3759-3761	of	event[201]	new[201]	_	_
22-18	3762-3773	CIA-derived	event[201]|abstract|abstract[203]	new[201]|new|giv[203]	_	_
22-19	3774-3777	MSC	event[201]|abstract[203]	new[201]|giv[203]	_	_
22-20	3778-3779	,	_	_	_	_
22-21	3780-3783	and	_	_	_	_
22-22	3784-3793	increased	abstract[205]	new[205]	_	_
22-23	3794-3809	differentiation	abstract|abstract[205]	new|new[205]	_	_
22-24	3810-3818	capacity	abstract[205]	new[205]	_	_
22-25	3819-3829	determined	abstract[205]	new[205]	_	_
22-26	3830-3832	by	abstract[205]	new[205]	_	_
22-27	3833-3836	the	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
22-28	3837-3847	expression	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
22-29	3848-3850	of	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
22-30	3851-3861	osteogenic	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-31	3862-3863	(	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-32	3864-3876	runt-related	abstract[205]|abstract[206]|abstract[208]|abstract[214]	new[205]|giv[206]|new[208]|new[214]	appos	22-37[0_208]
22-33	3877-3890	transcription	abstract[205]|abstract[206]|abstract|abstract[208]|abstract[214]	new[205]|giv[206]|new|new[208]|new[214]	_	_
22-34	3891-3897	factor	abstract[205]|abstract[206]|abstract[208]|abstract[214]	new[205]|giv[206]|new[208]|new[214]	_	_
22-35	3898-3899	2	abstract[205]|abstract[206]|abstract[208]|abstract[214]	new[205]|giv[206]|new[208]|new[214]	_	_
22-36	3900-3901	(	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-37	3902-3907	RUNX2	abstract[205]|abstract[206]|abstract|abstract[214]	new[205]|giv[206]|giv|new[214]	_	_
22-38	3908-3909	)	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-39	3910-3913	and	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-40	3914-3922	alkaline	abstract[205]|abstract[206]|substance|abstract[211]|abstract[214]	new[205]|giv[206]|new|new[211]|new[214]	appos	22-43[0_211]
22-41	3923-3934	phosphatase	abstract[205]|abstract[206]|abstract[211]|abstract[214]	new[205]|giv[206]|new[211]|new[214]	_	_
22-42	3935-3936	(	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-43	3937-3940	ALP	abstract[205]|abstract[206]|abstract|abstract[214]	new[205]|giv[206]|giv|new[214]	appos	22-52
22-44	3941-3942	)	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-45	3943-3944	)	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-46	3945-3946	,	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-47	3947-3950	and	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-48	3951-3963	chondrogenic	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-49	3964-3965	(	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-50	3966-3974	aggrecan	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-51	3975-3976	(	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-52	3977-3981	ACAN	abstract[205]|abstract[206]|abstract|abstract[214]	new[205]|giv[206]|giv|new[214]	_	_
22-53	3982-3983	)	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-54	3984-3985	)	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-55	3986-3993	markers	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-56	3994-3996	in	abstract[205]|abstract[206]|abstract[214]	new[205]|giv[206]|new[214]	_	_
22-57	3997-4002	basal	abstract[205]|abstract[206]|abstract[214]|abstract[215]	new[205]|giv[206]|new[214]|giv[215]	_	_
22-58	4003-4013	conditions	abstract[205]|abstract[206]|abstract[214]|abstract[215]	new[205]|giv[206]|new[214]|giv[215]	_	_
22-59	4014-4015	.	_	_	_	_
